CONVECTION‐ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN‐13‐PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL SAFETY RESULTS

OBJECTIVECintredekin besudotox (CB), a recombinant cytotoxin consisting of interleukin-13 and truncated Pseudomonas exotoxin, binds selectively to interleukin-13Rα2 receptors overexpressed by malignant gliomas. This study assessed the safety of CB administered by convection-enhanced delivery followed by standard external beam radiation therapy (EBRT) with or without temozolomide (Temodar; Schering-Plough, Kenilworth, NJ) in patients with newly diagnosed malignant gliomas. METHODSAfter gross total resection of the tumor, two to four intraparenchymal catheters were stereotactically placed and CB (0.25 or 0.5 μg/mL) was infused for 96 hours. This was followed, 10 to 14 days later, by EBRT (5940–6100 cGy, 5 d/wk for 6–7 wk) with or without temozolomide (75 mg/m2/d, 7 d/wk during EBRT). Safety was assessed during an 11-week observation period after catheter placement RESULTSTwenty-two patients (12 men, 10 women; median age, 55 yr; 21 with glioblastoma multiforme and one with an anaplastic mixed oligoastrocytoma) were enrolled. None of the patients experienced dose-limiting toxicities in the first two cohorts (0.25 μg/mL CB + EBRT [n = 3] and 0.25 μg/mL CB + EBRT + temozolomide [n = 3]). One patient experienced a dose-limiting toxicity (Grade 4 seizure) in the third cohort (0.5 μg/mL CB + EBRT [n = 6]). Six patients in the final cohort (0.5 μg/mL CB + EBRT + temozolomide [n = 10]) completed treatment, and one patient experienced a dose-limiting toxicity (Grade 3 aphasia and confusion). Four patients were not considered evaluable for a dose decision and were replaced. CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion. No Grade 3 to 4 hematological toxicities were observed. CONCLUSIONCB (0.5 μg/mL) administered via convection-enhanced delivery before standard radiochemotherapy seems to be well tolerated in adults with newly diagnosed malignant gliomas. Further clinical study assessment is warranted.

[1]  C. Wilson Glioblastoma: the past, the present, and the future. , 1992, Clinical neurosurgery.

[2]  Manfred Westphal,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[3]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.

[4]  P F Morrison,et al.  Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K R Hess,et al.  Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. , 1998, Neurosurgery.

[7]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[8]  P F Morrison,et al.  Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. , 1999, Journal of neurosurgery.

[9]  J. Connor,et al.  Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Berger,et al.  Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors , 2003, Journal of Neuro-Oncology.

[11]  Michael Weaver,et al.  Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[12]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Puri,et al.  Interleukin‐13 receptor as a unique target for anti‐glioblastoma therapy , 2001, International journal of cancer.

[14]  Wilson Cb Glioblastoma: the past, the present, and the future. , 1992 .

[15]  Barry W Wessels,et al.  Safety and Feasibility of Convection-enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 Patients , 2005, Neurosurgery.

[16]  Anthony Asher,et al.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma , 2003, Journal of Neuro-Oncology.

[17]  J. Berzofsky,et al.  Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13Rα2-Expressing Contralateral Tumors , 2006, Clinical Cancer Research.

[18]  R. Puri,et al.  Interleukin-13 Receptor-Directed Cytotoxin for Malignant Glioma Therapy: From Bench to Bedside , 2003, Journal of Neuro-Oncology.

[19]  R L Fine,et al.  Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model , 2000, Neurosurgery.

[20]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  R. Tanaka,et al.  Magnetic resonance imaging and histopathology of cerebral gliomas , 2004, Neuroradiology.

[22]  G. Barnett,et al.  Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma , 2000, Cancer Immunology, Immunotherapy.

[23]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[24]  R. Puri,et al.  Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. , 2000, Cancer research.

[25]  I. Pastan,et al.  Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  R. Puri,et al.  Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. , 2002, Molecular cancer therapeutics.

[27]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.

[28]  Susan M. Chang,et al.  Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. , 2005, Journal of neurosurgery.

[29]  P F Morrison,et al.  Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.

[30]  Mitchel S Berger,et al.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Oldfield,et al.  Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. , 1997, Journal of neurosurgery.

[32]  R. Puri,et al.  Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines. , 2005, International journal of radiation oncology, biology, physics.

[33]  P F Morrison,et al.  High-flow microinfusion: tissue penetration and pharmacodynamics. , 1994, The American journal of physiology.